Top Ten articles in the Pharma Industry this week
pharmafile | November 11, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â November, news, pharmaceutical, top 10, top ten, top ten storiesÂ
This week has seen pharmaceutical companies defending their patent protections and host of new collaboration spring up between companies. Read here to catch up on this and the other biggest news stories that have been viewed on our website.
10. Cancer Research UK enters new oncology partnership
The firm and its commercial arm haven entered into an agreement with TYG Oncology to develop a new vaccine for advanced cancers.
9. Coherus knocked back by AbbVie’s Humira patent protection
Coherus Biosciences, a developer of biosimilars, has suffered a blow in their petition for Inter Partes Review of one of AbbVie’s key formulation patents for Humira.
8. FDA clears digital sensor for GSK inhaler
Propeller Health’s digital sensor receives 510(k) clearance for use with GSK’s Ellipta dry powder inhaler.
7. NICE turns down Amgen’s multiple myeloma drug
Kyprolis (carfilzomib) is rejected by NICE for its routine use in the treatment of multiple myeloma in combination with Celgene’s Revlimid (lenalidomide) and dexamethasone or dexamethasone.
6. Pfizer’s breast cancer drug gets EU approval
The European Union has approved Ibrance following a positive recommendation from the European Medicines Agency (EMA) in September.
5. BenevolentAI announces licensing agreement with Janssen
BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, of Johnson & Johnson.
4. Collaboration on new therapeutic vaccine for HIV shows promise
Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into a new approach to combatting human immunodeficiency virus (HIV-1)..
3. FDA approves first therapy for paediatric psoriasis treatment
Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. This is the first such approval for the systemic therapy to treat paediatric patients from ages 4 to 17.
2. Pfizer to shut two out of three manufacturing plants in UK
Pfizer has announced that it will close two of the three manufacturing plants it still holds in the UK. The decision places at risk 370 jobs.
1. GSK launches patent infringement action against Pfizer
GSK attempts to protect its market share with allegations that Pfizer’s Trumenba copies its popular meningococcal group B vaccine Bexsero.
Related Content
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
